In Stock Cell Lines
Mus musculus (Mouse)
Liver
Adherent
The Npc1l1 Knockout Hepa 1-6 Cell Line is a CRISPR/Cas9-edited murine hepatocellular carcinoma model featuring targeted disruption of the Npc1l1 gene. Npc1l1 encodes a transporter critical for hepatic cholesterol absorption at the canalicular membrane, a process that regulates cholesterol homeostasis, bile acid synthesis, and downstream targets such as CYP7A1 and SREBP2. This loss-of-function model provides an essential tool for investigating liver-specific cholesterol metabolism, hypercholesterolemia, NAFLD, and gallstone disease. Key applications include cholesterol uptake assays, pharmacological inhibition studies with ezetimibe, and elucidation of NPC1L1-mediated endocytic signaling pathways.
LRIG1 Knockout K562 Polyclonal Cells
Cat. No. ARG19359
FoxM1 Knockout Lovo Polyclonal Cells
Cat. No. ARG11737
ACTN4 Knockout AGS Polyclonal Cells
Cat. No. ARG26454
KDM1B Knockout huh-7 Polyclonal Cells
Cat. No. ARG28465
GOLGA7 Knockout huh-7 Polyclonal Cells
Cat. No. ARG28203
Dog Intestinal Microvascular Endothelial Cell Medium
Cat. No. ARM0970
The Npc1l1 Knockout Hepa 1-6 Cell Line is a validated CRISPR/Cas9-edited knockout model derived from the murine Hepa 1-6 hepatoma line. This product features targeted disruption of the Npc1l1 gene, resulting in loss of Npc1l1 protein expression and function. The cell line serves as a defined genetic model for investigating hepatic cholesterol metabolism in the absence of canonical NPC1L1-mediated transport, providing a controlled system for studying liver-specific lipid handling pathways.
The parental Hepa 1-6 cell line is an established mouse hepatocellular carcinoma model originally derived from a BW7756 tumor in C57L/J mice. It retains key hepatocyte-specific functions, including de novo lipogenesis, bile acid synthesis, and lipid secretion, making it an ideal host for studying metabolic liver diseases. The sustained expression of relevant transcriptional regulators, such as SREBP2 and LXR??, in these cells supports the functional interrogation of cholesterol-responsive gene programs.
Npc1l1 encodes the Niemann-Pick C1-like 1 protein, which localizes to the hepatocyte canalicular membrane and mediates cholesterol absorption from bile. It binds cholesterol-rich micelles and facilitates internalization via clathrin-mediated endocytosis, interacting with the AP2 complex, flotillins, and Rab proteins. Npc1l1 expression is transcriptionally regulated by SREBP2 and LXR??, while its activity modulates intracellular cholesterol levels and downstream targets including CYP7A1. This positions Npc1l1 as a critical regulator of the enterohepatic circulation and cholesterol homeostasis.
In the context of hepatocellular carcinoma, Npc1l1 disruption provides a powerful tool for modeling dysregulated cholesterol absorption and biliary reabsorption. Loss of Npc1l1 function is known to attenuate diet-induced hypercholesterolemia and hepatic steatosis, making this knockout line highly relevant for non-alcoholic fatty liver disease and atherosclerosis research. The model enables precise separation of hepatic NPC1L1-dependent effects from the well-characterized intestinal role of NPC1L1, offering unique insights into liver-specific lipidology.
Researchers can utilize this knockout cell line for radiolabeled or fluorescent (NBD-cholesterol) cholesterol uptake assays to quantify transporter activity. It is ideally suited for NPC1L1 inhibitor screening, most notably for testing ezetimibe efficacy and mechanisms of action. Additional applications include Oil Red O staining to assess neutral lipid accumulation, RT-qPCR for profiling downstream targets such as Cyp7a1 and Srebp2, Western blotting for NPC1L1 and SREBP2 protein analysis, and mass spectrometry for bile acid profiling. For further technical specifications and ordering information, please contact Ascent Research.
